Intellia Therapeutics IPO: Regulatory Scrutiny Keeps Us Cautious
May 03, 2016 at 06:13 AM EDT
Intellia Therapeutics expects to price its Nasdaq IPO this Thurs., 5.5; lead underwriters for the deal are Credit Suisse, Jeffries, and Leerink Partners. We believe NTLA is an uncertain bet at present and suggest investors consider holding off.
